Aquinox Pharmaceuticals Inc. to Post Q3 2016 Earnings of ($0.58) Per Share, Leerink Swann Forecasts (AQXP)
Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) – Equities researchers at Leerink Swann issued their Q3 2016 earnings estimates for shares of Aquinox Pharmaceuticals in a research report issued to clients and investors on Tuesday. Leerink Swann analyst P. Matteis anticipates that the firm will earn ($0.58) per share for the quarter. Leerink Swann has a “Outperform” rating and a $24.00 price target on the stock. Leerink Swann also issued estimates for Aquinox Pharmaceuticals’ Q4 2016 earnings at ($0.56) EPS, FY2016 earnings at ($2.51) EPS and FY2017 earnings at ($2.63) EPS.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.22.
Several other research analysts have also weighed in on AQXP. Zacks Investment Research raised shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. Canaccord Genuity reissued a “buy” rating and set a $22.00 price objective on shares of Aquinox Pharmaceuticals in a research note on Wednesday, August 17th. Finally, Jefferies Group lifted their price objective on shares of Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a “hold” rating in a research note on Friday, August 5th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $20.29.
Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down 1.64% on Thursday, reaching $13.78. 95,213 shares of the company’s stock traded hands. The firm’s market cap is $237.18 million. The stock’s 50 day moving average is $12.19 and its 200 day moving average is $9.11. Aquinox Pharmaceuticals has a 52-week low of $6.01 and a 52-week high of $16.75.
In other news, major shareholder Bros. Advisors Lp Baker acquired 2,783,605 shares of the stock in a transaction dated Tuesday, September 20th. The stock was bought at an average price of $12.25 per share, with a total value of $34,099,161.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 3.00% of the stock is owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can bought a new stake in shares of Aquinox Pharmaceuticals during the second quarter valued at approximately $166,000. BlackRock Inc. boosted its stake in shares of Aquinox Pharmaceuticals by 24.3% in the first quarter. BlackRock Inc. now owns 50,600 shares of the company’s stock valued at $446,000 after buying an additional 9,900 shares during the last quarter. Bridgeway Capital Management Inc. boosted its stake in shares of Aquinox Pharmaceuticals by 416.7% in the second quarter. Bridgeway Capital Management Inc. now owns 62,000 shares of the company’s stock valued at $410,000 after buying an additional 50,000 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Aquinox Pharmaceuticals by 21.8% in the first quarter. Geode Capital Management LLC now owns 62,949 shares of the company’s stock valued at $555,000 after buying an additional 11,268 shares during the last quarter. Finally, Royce & Associates LP boosted its stake in shares of Aquinox Pharmaceuticals by 416.4% in the first quarter. Royce & Associates LP now owns 96,167 shares of the company’s stock valued at $848,000 after buying an additional 77,545 shares during the last quarter. Institutional investors and hedge funds own 68.20% of the company’s stock.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.
Receive News & Stock Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.